MannKind (MNKD) Expected to Announce Earnings on Wednesday

MannKind (NASDAQ:MNKD) is expected to be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect MannKind to post earnings of $0.03 per share and revenue of $74.99 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

MannKind Stock Performance

NASDAQ MNKD opened at $5.77 on Monday. MannKind has a twelve month low of $3.47 and a twelve month high of $7.63. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of 82.36 and a beta of 1.28. The firm’s 50 day moving average price is $6.06 and its two-hundred day moving average price is $6.28.

Analyst Ratings Changes

Several equities analysts have recently commented on MNKD shares. Royal Bank of Canada upgraded shares of MannKind from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $7.00 to $10.00 in a report on Thursday, December 19th. StockNews.com cut shares of MannKind from a “buy” rating to a “hold” rating in a report on Saturday, December 7th. Wedbush started coverage on shares of MannKind in a report on Monday, February 10th. They set an “outperform” rating and a $11.00 price target on the stock. Finally, Wells Fargo & Company started coverage on shares of MannKind in a report on Friday, December 20th. They set an “overweight” rating and a $9.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $9.21.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.